Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Ameriprise Financial Inc. decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,720,581 shares of the biotechnology company’s stock after selling 51,920 shares during the period. Ameriprise Financial Inc. owned approximately 0.83% of BioCryst Pharmaceuticals worth $12,939,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after buying an additional 1,583,826 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of BioCryst Pharmaceuticals by 25.1% in the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock worth $438,000 after buying an additional 11,711 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after acquiring an additional 91,998 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at about $80,000. Finally, Choreo LLC purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at about $106,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $10.24 on Monday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $5.92 and a 1 year high of $11.11. The company has a market cap of $2.14 billion, a P/E ratio of -16.79 and a beta of 1.08. The firm has a 50-day moving average of $8.11 and a 200 day moving average of $7.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the previous year, the business posted $0.28 EPS. The business’s revenue for the quarter was up 40.8% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BCRX has been the subject of several recent research reports. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price objective for the company. StockNews.com downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 14th. Royal Bank of Canada reissued an “outperform” rating and set a $13.00 price target (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. Finally, Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.